Interaction Checker

Interacciones de Ivabradina

Ivabradina (Corlanor) tiene 159 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 128; moderadas: 20; leves: 11; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (128)

  • AlfuzosinaalfabloqueanteGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Amitriptilinaantidepresivo tricíclicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Anagrelidafármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Aprepitantinhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Armodafiniloestimulante del SNCGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • AsenapinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • AtazanavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Azitromicinaantibiótico macrólidoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Grave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • CarbamazepinaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • CenobamatoanticonvulsivoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • CiclosporinainmunosupresorGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Cimetidinaantagonista H2Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • CiprofloxacinofluoroquinolonaGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • CitalopramISRSGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Claritromicinaantibiótico macrólidoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • ClobazambenzodiazepinaGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • CloroquinaantipalúdicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • ClorpromazinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • ClozapinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • DarunavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Darunavir y cobicistatantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Deferasiroxsuplemento de hierroGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Deutetrabenazinainhibidor de VMAT2Grave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • DexametasonacorticosteroideGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Diltiazembloqueador de los canales de calcioGrave

    Concurrent use of verapamil or diltiazem will increase Corlanor exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • DofetilidaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • DronedaronaantiarrítmicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Droperidolantagonista de la dopaminaGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • EfavirenzantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Eritromicinaantibiótico macrólidoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • EscitalopramISRSGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • EslicarbazepinaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • EtravirinaantirretroviralGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • EverolimusinmunosupresorGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • FenitoínaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Fentermina y topiramatoestimulante del SNCGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • FingolimodinmunosupresorGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • FlecainidaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • FluoxetinaISRSGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • FosamprenavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Fosaprepitantinhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • FosfenitoínaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Granisetrónfármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • GriseofulvinaantifúngicoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • HaloperidolantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • HidroxizinaantihistamínicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Hierba de San Juan (hipérico)Plantas medicinales y suplementosGrave

    La hierba de San Juan (hipérico) puede debilitar estos medicamentos al acelerar su descomposición, lo que puede significar rechazo del órgano, coágulos o pérdida de efecto. (NCCIH, St. John's Wort)

  • IbutilidaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • IloperidonaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Imatinibinhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • IsoniazidaantibióticoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Itraconazolantifúngico azólicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Ivacaftorinhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Ketoconazolantifúngico azólicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • LenacapavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • LevofloxacinofluoroquinolonaGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Lopinavir y ritonavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Lorlatinibinductor de CYP3A4Grave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • MetadonaopioideGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Mifepristonainhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Mirabegrónagonista beta-adrenérgicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Mitapivatinductor de CYP3A4Grave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Grave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • MoxifloxacinofluoroquinolonaGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Nafcilinaantibiótico del grupo de las penicilinasGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • NefazodonaantidepresivoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • NevirapinaantirretroviralGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Nilotinibfármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Nirmatrelvir y ritonavirantiviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • OfloxacinofluoroquinolonaGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Ondansetrónfármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • OxcarbazepinaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Grave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • PaliperidonaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Pentamidinafármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • PerampanelanticonvulsivoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • PimavanserinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • PimozidaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Pitolisantfármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Posaconazolantifúngico azólicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • PrimidonaanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • ProcainamidaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • PrometazinaantihistamínicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Prometazina y codeínaopioideGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Prometazina y dextrometorfanoantihistamínicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • QuetiapinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • QuinidinaantiarrítmicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • QuininaantipalúdicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • RifabutinaantibióticoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • RifampicinaantibióticoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • RifapentinaantibióticoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • RisperidonaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • RitonavirantirretroviralGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • SolifenacinaanticolinérgicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • SotalolbetabloqueanteGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Suvorexantsedante-hipnóticoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • Suzetriginainductor de CYP3A4Grave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • TacrolimusinmunosupresorGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Tetrabenazinainhibidor de VMAT2Grave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Ticagrelorantiagregante plaquetarioGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • TioridazinaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • TolterodinaanticolinérgicoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • TopiramatoanticonvulsivoGrave

    Avoid concomitant use of CYP3A4 inducers when using Corlanor. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Toremifenomodulador selectivo de los receptores de estrógenosGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • TramadolopioideGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Tramadol y paracetamolopioideGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • TrazodonaantidepresivoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Valbenazinainhibidor de VMAT2Grave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Grave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • VenlafaxinaIRSNGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Verapamilobloqueador de los canales de calcioGrave

    Concurrent use of verapamil or diltiazem will increase Corlanor exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

  • Voriconazolantifúngico azólicoGrave

    …bradycardia [see Warnings and Precautions ( 5.3 )] • Severe hepatic impairment [see Use in Specific Populations ( 8.6 )] • Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions ( 7.3 )] • Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions ( 7.1 )] Acute decompensated heart failure ( 4 ) (etiqueta de Ivabradina, Contraindicaciones)

  • ZiprasidonaantipsicóticoGrave

    Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etiqueta de Ivabradina, Advertencias y precauciones)

Interacciones moderadas (20)

  • AcebutololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • AtenololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Atenolol y clortalidonabetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • BetaxololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • BisoprololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • CarvedilolbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Digoxinaglucósido digitálicoModerada

    Risk factors for bradycardia include sinus node dysfunction, conduction defects (e.g., 1 st or 2 nd degree atrioventricular block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (e.g., digoxin, diltiazem, verapamil, amiodarone). (etiqueta de Ivabradina, Advertencias y precauciones)

  • Dorzolamida y timololinhibidor de la anhidrasa carbónicaModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • EsmololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • LabetalolbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • MetoprololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • NadololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • NebivololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • PindololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Pomelo (toronja)Alimentos y bebidasModerada

    Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [ s ee Warnings and Precautions ( 5.3 ) and Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • PropranololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

  • TimololbetabloqueanteModerada

    The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (etiqueta de Ivabradina, Interacciones medicamentosas)

Menciones leves (11)

  • Butalbital y paracetamolbarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico y cafeínabarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Butalbital, ácido acetilsalicílico, cafeína y codeínabarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Butalbital, paracetamol y cafeínabarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Butalbital, paracetamol, cafeína y codeínabarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Clotrimazolantifúngico azólicoLeve

    Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Econazolantifúngico azólicoLeve

    Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Fenobarbital, hiosciamina, atropina y escopolaminabarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Fidaxomicinaantibiótico macrólidoLeve

    Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. (etiqueta de Ivabradina, Interacciones medicamentosas)

  • MetohexitalbarbitúricoLeve

    John’s wort, rifampicin, barbiturates, and phenytoin [ s ee Clinical Pharmacology ( 12.3 )] . (etiqueta de Ivabradina, Interacciones medicamentosas)

  • Miconazolantifúngico azólicoLeve

    Examples of strong CYP3A4 inhibitors include azole antifungals (e.g., itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g., nelfinavir), and nefazodone. (etiqueta de Ivabradina, Interacciones medicamentosas)

Compruebe Ivabradina frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.